drugset / Trial / NCT01875380
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
Phase 2
Completed
46 enrolled
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Bayer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)
Timeline
- Start
- 2013-06
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 160 mg | Oral |